Community oncology practices need to come together as much as possible in order to respond to changes in the market, have a common voice, and to share best practices and learn from each other, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Community oncology practices need to come together as much as possible in order to respond to changes in the market, have a common voice, and to share best practices and learn from each other, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Transcript
What were the main takeaways from the Quality Cancer Care Alliance (QCCA) Winter Summit from the perspective of practice management?
The main takeaway that I walked away from the QCCA summit with is that this oncology world is getting more and more challenging. There’s so many things going on that we really need to work together as community oncology practices as much as possible in order to be able to respond to all the changes in the market, have a common voice about input we want to have in the market, and to also be able to benchmark with each other to have best practices and learn from each other.
There’s so many different things going on in so many different parts of the country, and a lot of times as a community oncology practice you feel sort of isolated, and what the QCCA program really did was give you a sense that there are a lot of other folks in the same boat with you and if we can all get on the same page and learn from each other and have a voice collectively we can make a difference.
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More